Therapeutic potential of lipopeptide biosurfactant-fabricated copper oxide nanoparticles: Mechanistic insight into their biocompatibility using zebra fish

Abstract

Nanoscale copper oxide (CuO NPs) with diameters in the 80–150 nm range has been biosynthesized using lipopeptide biosurfactant derived from Bacillus vallismortis and characterized by XRD and FE-SEM. The CuO NPs could be introduced as nanocarrier systems for combination therapy and a potential candidate for antibacterial, antioxidant, anticancer, and anti-diabetic activity. The antibacterial activity of CuO NPs was studied by incorporating the nanoparticles with fluorescent antibiotic Ciprofloxacin HCL (CIP) to form CIP@CuO NPs and tracked inside HEK-293 cell lines. The MIC values of CIP@CuO NPs against 1 × 10⁶ CFU ml⁻¹ Pseudomonas aeruginosa was determined to be 76 µg ml⁻¹and 69 µg ml⁻¹ against 1 × 10⁶ CFU ml⁻¹ Staphylococcus aureus. The CuO NPs were conjugated with the anticancer drug Doxorubicin (DOX) to form DOX@CuONPs, improving delivery toward cancer (HeLa) cells. The intracellular uptake of the drug-loaded CuO NPs was confirmed from confocal micrographs. Finally, the in vitro anti-diabetic activity of lipopeptide-coated CuO NPs was confirmed by the inhibitory activity of α-amylase. In contrast, the in vivo anti-diabetic efficacy of CuO NPs was validated by a significant reduction in blood glucose and glutathione levels. The CuO NPs positively affected the histopathological changes of the pancreas in induced diabetic mice. Cytotoxicity testing with Zebrafish demonstrated abnormal organ development with varying viability and hatching rates at 72 and 96 hpf, with an LC₅₀ of 45 µg/l. Aside from the various potential medicinal characteristics, the study provided valuable information on cytotoxic impact, which can be used in future investigations of their eco-toxicological impacts.